remainder of each sequence was assembled on a CEM Liberty TM microwave peptide synthesizer (Buckingham, UK). The side chain-protecting groups used were trifluoroacetic acid-labile, except for 1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl (ivDde) for Lys which was hydrazine-labile. Peptides were synthesized on a 0.1 mmol scale using a 5-fold excess of Fmoc-protected amino acids (0.5 mmol), which were activated using PyBOP (5-fold excess) in the presence of DIEA.
Piperidine (20% v/v) in DMF was used to remove Nα-Fmoc protecting groups. The coupling was carried out once at 75 °C for 5 min, except for histidine which was coupled at 50 °C for 10 min at 60 watt microwave power. The deprotection was carried out at 75 °C twice, once for 30 sec and then for 3 min at 35 watt microwave 
Peptide-PMO conjugation and purification
A 25-mer PMO antisense sequence for mouse dystrophin exon-23 (GGCCAAACCTCGGCTTACCTGAAAT) was purchased from Gene Tools Inc.
(Philomath, USA). Peptides were conjugated to the 3'-end of the PMO through its Cterminal carboxyl group. This was activated using a 2.5 and 2-fold excess of HBTU and HOAt in NMP respectively in the presence of 2.5 eq. of DIEA and a 2-fold
Electronic Supplementary Material (ESI) for Chemical Communications This journal is © The Royal Society of Chemistry 2013
excess of peptide over PMO dissolved in dimethylsulfoxide (DMSO) was used. The reaction was carried out at 40 °C for 2 h. The ivDde protecting group of Lys in Tet1
was removed by addition of 20 eq. of hydrazine (cf ivDde) to the reaction mixture and incubation at room temperature for 30 min. The reaction was stopped by addition of water. Pip6a-(alkyne)-PMO was purified on a high-resolution (HR)-16 cationexchange column (GE Healthcare, USA) using 25 mM sodium phosphate buffer (pH 7.2) containing 25% acetonitrile. 1 M NaCl solution was used to elute the peptide from the column at a flow rate of 6 ml min -1 . Due to the lack of sufficient charge to retain Tet1-(alkyne)-PMO conjugate on an ion-exchange column, it was purified using RP-HPLC. In the case of Pip6a-(alkyne)-PMO, the excess salts were removed by filtering the fractions collected after ion-exchange using an Amicon ® Ultra-15 3K centrifugal filter device. Removal of any TFA counter-ions from the Tet1-(alkyne)-PMO conjugate was carried out by dissolving the lyophilized conjugate in 5 mM HCl solution followed by filtration. The concentrate (~250 µl) was further diluted by addition of 10 ml of 5 mM HCl solution and filtered again. Finally, the concentrate was washed twice with de-ionised water before lyophilisation.
Post-conjugation labelling of Peptide-PMO conjugates
The alkyne functionalized PPMOs were labelled with Cy5-azide (Lumiprobe Life Science Solutions, Florida, USA) using copper (I) mediated alkyne-azide click chemistry. PPMOs were dissolved in 30% DMSO followed by addition of Cy5-azide (1.5 eq. in DMSO). Sodium ascorbate (20 eq. as a 20 mM solution) was added and the reaction mixture was vortexed thoroughly followed by addition of copper (II)-TBTA (21 eq. as a 20 mM solution) which was prepared by mixing equal amounts of 40 mM the Cy5-labelled PPMOs were purified and desalted as described above.
MALDI-TOF mass spectral characterization of peptides and PPMO
Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS, ABI Voyager DE Pro) was used to characterize the peptides and PPMOs. Mass accuracy on this equipment is expected to be ± 0.1%. Based on the 
Cell culture and transfection
Mouse H2K/mdx myoblasts were maintained in high-glucose Dulbecco's modified Eagles's medium (DEME) supplemented with 20% foetal calf serum, 2% chicken embryo extract (CEE) and 0.002% of interferon-γ at 33 °C. The myoblast cells were differentiated into myotubes for the exon-skipping assay. Myoblasts were plated at a density of 5 × 10 5 cells per 1 ml per well in 24 well plates that were pre-coated with 0.01% gelatin. Cells were allowed to reach >90% confluent in DEME with 20% FCS / 2% CEE / 0.002 % interferon-γ at 33 °C. They were washed with PBS twice and the media was changed to DEME supplemented with 5% horse serum (HS) and transferred to 37 °C. Cells were washed with PBS and fresh 5% HS media was added for 1 min. The products were separated by electrophoresis using 1.5% agarose gel.
Data analysis
The images of agarose gels were taken on a Molecular Imager ChemiDoc™ XRS + imaging system (BioRad, UK) and the images were analysed using Image Lab (V4.1).
Graphpad PRISM 6 was used to analyze and plot the exon-skipping assay data, which were expressed as percentages of exon-23 skipping from at least three independent experiments. The confocal microscopy images were processed with ZEN2010 software.
Supp. Fig. 1 MALDI-TOF mass spectra of TET1-PMO conjugate. (A) Mass spectrum profile of TET1-PMO conjugate after purification using 0.1% TFA-based buffer. (B) After lyophilisation, the conjugate was dissolved in 5 mM HCl and lyophilised again, which led to the degradation of the PMO. (C) The lyophilised TET1-PMO was dissolved in 5 mM HCl and desalted using a 3K Amicon filtration device. The concentrate was further diluted in 5 mM HCl and filtered again. The concentrate was washed twice with H 2 O by adding deionised H 2 O and filtered. The concentrated was lyophilised and the conjugate was found to be intact.
